Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.
NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
When Crohn’s disease forced Sunny Dee to put her dance career on hold, she built a community through podcasting. Learn how she’s staying optimistic in the face of chronic illness. (Partner Content)
AbbVie sees potential Botox and filler demand from GLP-1 users as small studies show improved facial satisfaction after cosmetic treatments.
These are arguably among the most reliable dividend payers.
AbbVie (ABBV) agrees to buy exclusive global rights to develop and commercialize a bowel disease drug from Nxera Pharma in a deal worth up to $1.5B. Read more here.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties.NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease. Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharm
Tipranks Press Release.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
AbbVie stock still trades at a premium to our new valuation.
This is the newest page. Registered accounts read further back.